Charles H. Ballow

3.9k total citations · 1 hit paper
44 papers, 3.1k citations indexed

About

Charles H. Ballow is a scholar working on Infectious Diseases, Pharmacology and Epidemiology. According to data from OpenAlex, Charles H. Ballow has authored 44 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Infectious Diseases, 18 papers in Pharmacology and 17 papers in Epidemiology. Recurrent topics in Charles H. Ballow's work include Antibiotics Pharmacokinetics and Efficacy (17 papers), Pneumonia and Respiratory Infections (14 papers) and Antimicrobial Resistance in Staphylococcus (11 papers). Charles H. Ballow is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (17 papers), Pneumonia and Respiratory Infections (14 papers) and Antimicrobial Resistance in Staphylococcus (11 papers). Charles H. Ballow collaborates with scholars based in United States, Germany and United Kingdom. Charles H. Ballow's co-authors include Jerome J. Schentag, Alan Forrest, Mary C. Birmingham, David E. Nix, Thomas F. Goss, Sujata M. Bhavnani, Ronald N. Jones, Douglas J. Biedenbach, Jerome J. Schentag and Judith M. Hyatt and has published in prestigious journals such as The American Journal of Medicine, Antimicrobial Agents and Chemotherapy and Biochemical Pharmacology.

In The Last Decade

Charles H. Ballow

44 papers receiving 3.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

1993 906 citations Alan Forrest, David E. Nix et al. Antimicrobial Agents and Chemotherapy profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Charles H. Ballow United States	24	1.7k	1.2k	1.2k	804	675	44	3.1k
Mary C. Birmingham United States	19	2.0k 1.1×	1.2k 1.0×	925 0.8×	1.4k 1.8×	935 1.4×	32	4.3k
Evelyn J. Ellis‐Grosse United States	24	1.5k 0.9×	855 0.7×	1.8k 1.5×	813 1.0×	630 0.9×	42	2.8k
Sheryl Zelenitsky Canada	31	2.1k 1.2×	1.3k 1.1×	2.0k 1.7×	1.0k 1.3×	555 0.8×	80	4.3k
Alfred S. Gin Canada	22	1.6k 0.9×	1.1k 0.9×	1.8k 1.5×	846 1.1×	408 0.6×	37	3.4k
Charles H. Nightingale United States	38	3.1k 1.8×	2.0k 1.6×	1.9k 1.6×	950 1.2×	525 0.8×	209	5.1k
Christian Joukhadar Austria	40	1.9k 1.1×	1.3k 1.1×	865 0.7×	1.0k 1.3×	632 0.9×	100	4.4k
David S. Burgess United States	34	1.4k 0.8×	1.1k 0.9×	1.2k 1.0×	744 0.9×	344 0.5×	119	3.4k
John A. Bosso United States	30	1.3k 0.8×	933 0.8×	978 0.8×	794 1.0×	427 0.6×	120	3.7k
Nathalie Dartois France	21	902 0.5×	851 0.7×	1.2k 1.0×	587 0.7×	460 0.7×	30	2.5k
Joseph A. Paladino United States	25	1.2k 0.7×	965 0.8×	581 0.5×	423 0.5×	392 0.6×	78	2.3k

Countries citing papers authored by Charles H. Ballow

Since Specialization

Citations

This map shows the geographic impact of Charles H. Ballow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles H. Ballow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles H. Ballow more than expected).

Fields of papers citing papers by Charles H. Ballow

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles H. Ballow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles H. Ballow. The network helps show where Charles H. Ballow may publish in the future.

Co-authorship network of co-authors of Charles H. Ballow

This figure shows the co-authorship network connecting the top 25 collaborators of Charles H. Ballow. A scholar is included among the top collaborators of Charles H. Ballow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles H. Ballow. Charles H. Ballow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fong, Regan, et al.. (2018). Effects of a State‐ and Use‐Dependent Nav1.7 Channel Blocker on Ambulatory Blood Pressure: A Randomized, Controlled Crossover Study. The Journal of Clinical Pharmacology. 59(1). 90–97. 6 indexed citations

Wong, Shekman, Michael R. Goldberg, Charles H. Ballow, Michael M. Kitt, & Steven L. Barriere. (2010). Effect of Telavancin on the Pharmacokinetics of the Cytochrome P450 3A Probe Substrate Midazolam: A Randomized, Double‐Blind, Crossover Study in Healthy Subjects. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 30(2). 136–143. 17 indexed citations

Wire, Mary Beth, Charles H. Ballow, Sandra L. Preston, et al.. (2004). Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers. AIDS. 18(6). 897–907. 29 indexed citations

Bolmström, Anne, et al.. (2002). Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from the Zyvox® antimicrobial potency study (ZAPS-Europe). Clinical Microbiology and Infection. 8(12). 791–800. 33 indexed citations

Smith, Patrick F., Alan Forrest, John M. Adams, & Charles H. Ballow. (2002). Effect of Food on the Pharmacokinetics of (‐) and (+) dOTC When Administered as an Oral Racemate. The Journal of Clinical Pharmacology. 42(6). 658–661. 1 indexed citations

Ballow, Charles H., Ronald N. Jones, & Douglas J. Biedenbach. (2002). A multicenter evaluation of linezolid antimicrobial activity in North America. Diagnostic Microbiology and Infectious Disease. 43(1). 75–83. 62 indexed citations

Ballow, Charles H., Douglas J. Biedenbach, Flávia Rossi, & Ronald N. Jones. (2002). Multicenter assessment of the linezolid spectrum and activity using the disk diffusion and Etest methods: report of the Zyvox® Antimicrobial Potency Study in Latin America (LA-ZAPS). The Brazilian Journal of Infectious Diseases. 6(3). 100–9. 17 indexed citations

Smith, Patrick F., et al.. (2001). Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients. Clinical Therapeutics. 23(8). 1231–1244. 59 indexed citations

Smith, Patrick F., et al.. (2000). Absolute Bioavailability and Disposition of (−) and (+) 2′-Deoxy- 3′-Oxa-4′-Thiocytidine (dOTC) following Single Intravenous and Oral Doses of Racemic dOTC in Humans. Antimicrobial Agents and Chemotherapy. 44(6). 1609–1615. 5 indexed citations

10.

Bhavnani, Sujata M., et al.. (2000). A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia☆. Diagnostic Microbiology and Infectious Disease. 36(3). 145–158. 158 indexed citations

11.

Ballow, Charles H., et al.. (1998). Pharmacokinetics of Oral Azithromycin in Serum, Urine, Polymorphonuclear Leucocytes and Inflammatory vs Non-Inflammatory Skin Blisters in Healthy Volunteers. Clinical Drug Investigation. 15(2). 159–167. 38 indexed citations

12.

Ballow, Charles H., et al.. (1997). Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. Diagnostic Microbiology and Infectious Disease. 29(3). 173–186. 30 indexed citations

13.

Hyatt, Judith M., Aileen B Luzier, Alan Forrest, Charles H. Ballow, & Jerome J. Schentag. (1997). Modeling the response of pneumonia to antimicrobial therapy. Antimicrobial Agents and Chemotherapy. 41(6). 1269–1274. 10 indexed citations

14.

Kashuba, Angela D. M., Charles H. Ballow, & Alan Forrest. (1996). Development and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidime. Antimicrobial Agents and Chemotherapy. 40(8). 1860–1865. 16 indexed citations

15.

Amsden, Guy W. & Charles H. Ballow. (1996). Prospective Validation of an Optimal Sparse Plasma‐Sampling Strategy for Estimating Ciprofloxacin Pharmacokinetics. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 16(5). 937–941. 3 indexed citations

16.

Forrest, Alan, Charles H. Ballow, David E. Nix, Mary C. Birmingham, & Jerome J. Schentag. (1993). Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrobial Agents and Chemotherapy. 37(5). 1065–1072. 114 indexed citations

17.

Ballow, Charles H. & Jerome J. Schentag. (1992). Trends in antibiotic utilization and bacterial resistance. Diagnostic Microbiology and Infectious Disease. 15(2). 6–6. 133 indexed citations

18.

Schentag, Jerome J. & Charles H. Ballow. (1991). Tissue-directed pharmacokinetics. The American Journal of Medicine. 91(3). S5–S11. 152 indexed citations

19.

Leo, Raphael J. & Charles H. Ballow. (1991). Seizure Activity Associated with Imipenem Use: Clinical Case Reports and Review of the Literature. DICP. 25(4). 351–354. 27 indexed citations

20.

Kauffman, Frederick C., et al.. (1980). Effects of 3-methylcholanthrene on oxidized nicotinamide-adenine dinucleotide phosphatedependent dehydrogenases and selected metabolites in perfused rat liver. Biochemical Pharmacology. 29(5). 697–700. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact